Homograft Implantation for Aortic Valve Replacement Since 15 Years: Results and Follow-up
DOI:
https://doi.org/10.1532/HSF98.20091160Abstract
Background: The use of homografts in aortic valve replacement is an alternative to other prostheses and has been established in our department for 15 years.
Methods: Since 1992, 360 homografts (HG) have been implanted in adult patients (mean age 51.6 years, 72.8% male). Prospective follow-up was done on an annual basis.
Results: Thirty-day mortality was 5.0% (n = 17); after 5, 10, and 15 years, survival was 88.3%, 84.6%, and 76.0%, respectively. Out of 39 late deaths, 11 were valve-related (10 HG infections, 1 aortic aneurysm). Freedom from reoperation was 99.4% 1 year after operation; after 5, 10, and 15 years it was 94.1%, 78.2%, and 67.3%, respectively. Indications for HG explantation were graft infections (n = 20), calcification (n = 16), regurgitation > grade II (n = 17), perforation (n = 8), and paravalvular leakage (n = 1). Eleven transitoric ischemic attacks, 2 strokes, and 1 cerebral bleeding event were recorded. In echocardiography, the transvalvular pressure gradient changed from 10.55 to 15.02 (P = .004), 19.9 mmHg (P = .056), and 37 mmHg (not applicable) after 5, 10, and 15 years, respectively. Mean HG regurgitation was grade 0.49 before discharge and increased to 1.0 (P < .001), 0.91, and 2.5 after 5, 10, and 15 years, respectively. Ejection fraction increased from 61.9% to 64% after 5 years and to 66% after 10 years (P = .021) and then decreased to 63.5% after 15 years.
Conclusions: Comparing HG with other valve prostheses, survival and graft durability seem to be confirmed. They are vulnerable to infections. The hemodynamic performance is good, and hemorrhagic or thrombo-embolic events are rare.
References
Akins CW, Miller DC, Turina MI, et al. 2008. Guidelines for reporting mortality and morbidity after cardiac valve interventions. J Thorac Cardiovasc Surg 135:732-8.nBanbury MK, Cosgrove DM 3rd, Thomas JD, et al. 2002. Hemodynamic stability during 17 years of the Carpentier-Edwards aortic pericardial bioprosthesis. Ann Thorac Surg 73:1460-5.nBarratt-Boyes BG, Roche AH, Brandt PW, Smith JC, Lowe JB. 1969. Aortic homograft valve replacement. A long-term follow-up of an initial series of 101 patients. Circulation 40:763-75.nBorger MA, Ivanov J, Armstrong S, Christie-Hrybinsky D, Feindel CM, David TE. 2006. Twenty-year results of the Hancock II bioprosthesis. J Heart Valve Dis 15:49-55.nFischlein T, Schütz A, Haushofer M, et al. 1995. Immunologic reaction and viability of cryopreserved homografts. Ann Thorac Surg 60(2 Suppl):S122-6.nFrater RW, Furlong P, Cosgrove DM, et al. 1998. Long-term durability and patient functional status of the Carpentier-Edwards Perimount pericardial bioprosthesis in the aortic position. J Heart Valve Dis 7:48-53.nGerosa G, Ross DN, Brucke PE, et al. 1994. Aortic valve replacement with pulmonary homografts: early experience. J Thorac Cardiovasc Surg 107:424-36.nGorczynski A, Trenkner M, Anisimowicz L, et al. 1982. Biomechanics of the pulmonary autograft valve in the aortic position. Thorax 37:535-9.nGulbins H, Kilian E, Roth S, Uhlig A, Kreuzer E, Reichart B. 2002. Is there an advantage in using homografts in patients with acute infective endocarditis of the aortic valve? J Heart Valve Dis 11:492-7.nHehrlein FW. 1971. Preservation problems of homologous and heterologous aortic valve grafts [in German]. Thoraxchir Vask Chir 19:394-5.nHiemann NE, Knosalla C, Wellnhofer E, Lehmkuhl HB, Hetzer R, Meyer R. 2008. Beneficial effect of female gender on long-term survival after heart transplantation. Transplantation 86:348-56.nJin XY, Zhang ZM, Gibson DG, Yacoub MH, Pepper JR. 1996. Effects of valve substitute on changes in left ventricular function and hypertrophy after aortic valve replacement. Ann Thorac Surg 62:683-90.nKilian E, Oberhoffer M, Gulbins H, Uhlig A, Kreuzer E, Reichart B. 2004. Ten years' experience in aortic valve replacement with homografts in 389 cases. J Heart Valve Dis. 13:554-9.nLund O, Chandrasekaran V, Grocott-Mason R, et al. 1999. Primary aortic valve replacement with allografts over twenty-five years: valve-related and procedure-related determinants of outcome. J Thorac Cardiovasc Surg 117:77-90.nMair R, Harringer W, Wimmer-Greinecker G, et al. 1995. Aortic valve replacement with cryopreserved pulmonary allografts: five years' follow-up. Ann Thorac Surg 60:S185-8.nNaegele H, Bohlmann M, Döring V, Kalmar P, Rödiger W. 2000. Results of aortic valve replacement with pulmonary and aortic homografts. J Heart Valve Dis 9:215-20.nNiwaya K, Knott-Craig CJ, Santangleo K, Lane MM, Chandrasekaran K, Elkins RC. 1999. Advantage of autograft and homograft valve replacement for complex aortic valve endocarditis. Ann Thorac Surg 67:1603-8.nO'Brien MF, Stafford G, Gardner M, et al. 1987. The viable cryopreserved allograft aortic valve. J Card Surg 2(1 Suppl):153-67.nO'Brien MF, Harrocks S, Stafford EG, et al. 2001. The homograft aortic valve: a 29-year, 99.3% follow up of 1,022 valve replacements. J Heart Valve Dis 10:334-44.nRiberi A, Caus T, Mesana T, et al. 1997. Aortic valve or root replacement with cryopreserved homograft for active infectious endocarditis. Cardiovasc Surg 5:579-83.nRoss DN. 1962. Homograft replacement of the aortic valve. Lancet 2:487-93.nSchütz A, Fischlein T, Haushofer M, et al. 1993. Homografts aus der eigener Herzklappenbank [Homografts from an own valve bank]. Zeitschrift für Transplantationsmedizin 5:194-8.nYacoub M, Kittle CF. 1970. Sterilization of valve homografts by antibiotic solutions. Circulation 41(5 Suppl):II29-32.nYacoub M, Rasmi NR, Sundt TM, et al. 1995. Fourteen-year experience with homovital homografts for aortic valve replacement. J Thorac Cardiovasc Surg 110:186-193.n
